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Alzheimer's disease (AD), which is one of the neurodegenerative diseases, is the most common form 
of dementia. The general symptoms associated with AD include memory loss, cognitive impairment, 
and loss of identity. Although much research has been conducted to elucidate the etiology of AD and 
develop a drug for curing the disease, it has been very challenging due to its complex nature. The 
accumulation of aggregated amyloid- (A) peptides is observed as a pathological hallmark in the AD-
affected brain. In addition, other pathological features [e.g., dyshomeostasis of metal ions and 
overproduction of reactive oxygen species (ROS) leading to oxidative stress] are also shown in the brain 
of AD. Moreover, it has been reported that these pathological elements, including A peptides, metal 
ions, and ROS could be interconnected with each other. For instance, redox-active metal ions can 
accelerate the rate of A aggregation and stabilize the toxic A aggregates, such as structured oligomers. 
Furthermore, redox-active metal ions are able to interact with A species forming metal-bound A 
(metal–A) complexes that can generate ROS through Fenton-like reactions. Therefore, in order to 
effectively treat AD, it is necessary to elucidate an inter-relationship among multiple pathogenic factors. 
The studies presented in this thesis exhibit the development of chemical tools for targeting and 
regulating multiple pathogenic components found in the brain of AD. Chapter 1 describes a minimalistic 
redox-based design strategy for engineering compact molecules based on a simplest aromatic 
framework, benzene, with multi-reactivity against multiple pathological factors of AD. In Chapter 2, 
investigations of fluorescent probes for monitoring metal ions in biological systems are summarized. 
Collectively, our overall studies and findings, presented in this thesis, demonstrate the feasibility of 
establishing effective and efficient design strategies to target and regulate multiple factors found in AD 
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reference electrode); [AgNO3] = 0.01 M (for reference electrode); N2 (g); scan rates = 25, 50, 100, 150, 
200, and 250 mV/s; three electrodes: glassy carbon working electrode, Ag/Ag(I) reference electrode, 
and platinum counter electrode; room temperature. 
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0.1 M (for supporting electrolyte and reference electrode); [AgNO3] = 0.01 M (for reference electrode); 
N2 (g); scan rates = 25, 50, 100, 150, 200, and 250 mV/s; three electrodes: glassy carbon working 
electrode, Ag/Ag(I) reference electrode, and platinum counter electrode; room temperature. 
 
Figure 1.5. Scavenging capability of compounds against free organic radicals, determined by the TEAC 
assay employing cell lysates. The TEAC values are relative to that of an analog of vitamin E, Trolox 
(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). The error bars indicate the standard error 
from four independent experiments. ∗TEAC values of 5–10 were not obtained due to no measurable 
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Figure 1.6. Effects of 1–5 on the formation of metal-free or metal-induced A40 aggregates. (a) Scheme 
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of the inhibition experiments. (b-d) Gel/Western blots (an A antibody, 6E10) of the A40 species 
generated in the (b) absence and (c and d) presence of metal ions. Lanes: (C) A40; (1) A40 + 1; (2) 
A40 + 2; (3) A40 + 3; (4) A40 + 4; (5) A40 + 5. (e) TEM images of the samples obtained from (b) 
metal-free A40 and A40 with 1 equiv of (c) Cu(II) and (d) Zn(II). Conditions: [A40] = 25 M; [Cu(II) 
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agitation. Scale bar = 200 nm. 
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of the disaggregation experiments. (b-d) Gel/Western blots (6E10) of the A40 species generated in the 
(b) absence and (c and d) presence of metal ions. Lanes: (C) A40; (1) A40 + 1; (2) A40 + 2; (3) A40 
+ 3; (4) A40 + 4; (5) A40 + 5. (e) TEM images of the samples obtained from (b) metal-free A40 and 
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absence and (c and d) presence of metal ions. Lanes: (C) A42; (1) A42 + 1; (2) A42 + 2; (3) A42 + 3; 
(4) A42 + 4; (5) A42 + 5. (e) TEM images of the samples obtained from (b) metal-free A42 and A42 
with 1 equiv of (c) Cu(II) and (d) Zn(II). Conditions: [A42] = 25 M; [Cu(II) or Zn(II)] = 12.5, 25, and 
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absence and (c and d) presence of metal ions. Lanes: (C) A42; (1) A42 + 1; (2) A42 + 2; (3) A42 + 3; 
(4) A42 + 4; (5) A42 + 5. (e) TEM images of the samples obtained from (b) metal-free A42 and A42 
with 1 equiv of (c) Cu(II) and (d) Zn(II). Conditions: [A42] = 25 M; [Cu(II) or Zn(II)] = 12.5, 25, and 
50 M; [compound] = 50 M; 20 mM HEPES, pH 7.4 [for metal-free or Zn(II)-containing samples] or 
pH 6.6 [for Cu(II)-added samples], 150 mM NaCl; 37 °C; 24 h; constant agitation. Scale bar = 200 nm. 
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Scheme of the inhibition and disaggregation experiments. (b and c) Analysis of the resultant (b) A40 
and (c) A42 species by gel/Western blot (6E10). Lanes: (C) A40/42; (6) A40/42 + 6; (7) A40/42 + 7; (8) 
A40/42 + 8; (9) A40/42 + 9; (10) A40/42 + 10. Conditions: [A40/42] = 25 M; [Cu(II) or Zn(II)] = 25 M; 
[compound] = 50 M; 20 mM HEPES, pH 7.4 [for metal-free or Zn(II)-containing samples] or pH 6.6 
[for Cu(II)-added samples], 150 mM NaCl; 37 °C; 24 h; constant agitation. 
 
Figure 1.11. Analyses of 1’s transformation and interaction with metal-free A40 or Cu(II)-associated 
A40 as well as proposed mechanisms. (a) Transfiguration of 1 in the presence of A40 with or without 
Cu(II), detected by UV–Vis spectroscopy. Conditions: [A40] = 25 M; [Cu(II)] = 25 M; [1] = 50 M; 
20 mM HEPES, pH 7.4 (for metal-free samples) or pH 6.6 [for Cu(II)-added samples], 150 mM NaCl; 
37 °C; 0–24 h; no agitation. (b-d) Interactions of 1 with metal-free A40 and Cu(II)-treated A40, 
analyzed by ESI–MS, ESI–MS2, and MALDI–MS. A40 monomer incubated with 1 in the (b and d) 
absence and (d) presence of Cu(II) was detected by (b) ESI–MS or (d) MALDI–MS. Oxidized A40 and 
an adduct between A40 and oxidatively transformed 1 (i.e., BQ) are indicated with red and blue circles, 
respectively. The covalent bond with A40 (green circle) was only observed from 1-treated samples. (c) 
ESI–MS2 spectrum of the singly oxidized A404+ produced upon addition of 1. Conditions (for ESI–MS 
studies): [A40] = 50 M; [1] = 100 M; 1 mM ammonium acetate, pH 7.4; 37 °C; 24 h; no agitation. 
The samples were diluted by 10 fold with ddH2O before injection to the mass spectrometer. Conditions 
(for MALDI–MS measurements): [A40] = 25 M; [Cu(II)] = 25 M; [1] = 50 M; pH 7.4 (for metal-
free samples) or pH 6.6 [for Cu(II)-added samples]; 37 °C; 24 h; constant agitation. (e) Two proposed 
pathways: (left) peptide oxidation by 1; (right) Formation of a covalent adduct between A and 
oxidatively transformed 1 (i.e., BQ). 
 
Figure 1.12. Transformation of 1–10 in the absence and presence of A40 with or without metal ions, 
detected by UV–Vis spectroscopy. Conditions: [A40] = 25 M; [Cu(II) or Zn(II)] = 25 M; [compound] 
= 50 M; 20 mM HEPES, pH 7.4 [for metal-free or Zn(II)-containing samples] or pH 6.6 [for Cu(II)-
added samples], 150 mM NaCl; 37 °C; 0-24 h; no agitation.  
 
Figure 1.13. Docking studies of 1–5 with A40 monomer (PDB 2LFM). (a) Docked conformations of 
compounds with A40 (surface and zoon-in images). Hydrogen bonding between compounds and A40 
is indicated with gray dashed lines (2.2-2.7 Å). The self-recognition site in A40 is highlighted in yellow. 
(b) Binding energy of the compounds with A40 monomer. 
 
Figure 1.14. Interactions of 1–5 with metal-free and metal-treated A40. A40 monomer incubated (a) 
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with 2–5 in the absence of metal ions and (b) with 1 in presence of Zn(II) was monitored by (a) ESI–
MS and (b) MALDI–MS. Oxidized ions of A40 and A40–BQ adducts are indicated with red and blue 
circles, respectively. The covalent adducts between A40 and oxidatively transformed 1–4 (i.e., BQ) are 
indicated with green circles. Conditions (for ESI–MS studies): [A40] = 50 M; [compound] = 100 M; 
1 mM ammonium acetate, pH 7.4; 37 °C; 24 h; no agitation. The samples were diluted by 10 fold with 
ddH2O before injection to the mass spectrometer. Conditions (for MALDI–MS measurements): [A40] 
= 25 M; [Zn(II)] = 25 M; [1] = 50 M; pH 7.4; 37 °C; 24 h; constant agitation. 
 
Figure 1.15. Cytotoxicity of 1–4. Cell viability (%) of N2a cells incubated with various concentrations 
of 1–4 was obtained by the MTT assay. Error bars indicate the standard error from four independent 
experiments. Conditions: [compound] = 5, 10, 25, and 50 M (1 % v/v DMSO); 37 °C; 24 h. 
 
Figure 1.16. Analysis of the amounts of A species in 1- or BQ-treated 5XFAD mice. (a) Levels of 
soluble A42, insoluble A42, total A42, and oligomeric A were analyzed in triplicate per sample by 
ELISA. Lanes: (Vehicle) 5XFAD + vehicle; (BQ) 5XFAD + BQ; (1) 5XFAD + 1. (b) Loads of amyloid 
deposits and plaques in the brain expressed as the percent area of 4G8-immunoreactive deposits or the 
number of congophilic plaques per mm2 of a region of interest, which was taken from hippocampal 
(hip), cortical (ctx) and thalamic (tlm) areas. (c) Representative images of 4G8-immunoreactive (1st row) 
or Congo red-positive (2nd and 3rd rows) amyloid deposits or plaques in hip and ctx (1st and 3rd rows), 
or tlm (2nd row) regions in the brains of vehicle- (1st column), BQ- (2nd column), or 1-treated (3rd column) 
5XFAD mice are shown. Congo red stained brain sections were also counter-stained with haematoxylin 
to differentiate the nuclei of neural cells (2nd and 3rd rows). Subiculum (sub), corpus callosum (cc), and 
fornix (fx). Scale bars = 500 m (white) or 200 m (black). The measurements were performed in five 
sagittal sections taken every 200 m from midline per animal. Bars denote mean ± standard errors of 
mean (s.e.m.) (animal numbers; n = 19 for vehicle-treated 5XFAD mice; n = 9 for BQ-treated 5XFAD 
mice; n = 12 for 1-treated 5XFAD mice). ∗P < 0.05, or ∗∗P < 0.01 by unpaired two-tail t-test. 
  
Figure 1.17. Measurement of spatial learning and memory improvements in 1- or BQ-administrated 
5XFAD mice. (a) Escape latency time daily assessed for five days from the day of the 30th compound 
treatment in the Morris water maze (MWM) test. From the 2nd training trial to the 5th trial, the latency 
time became significantly shorter in non-transgenic wild-type mice (WT; P = 0.012 by one-way 
ANOVA with Student-Newman-Keuls post hoc test) or 1-treated 5XFAD mice (1; P = 0.0017), but not 
in vehicle- (Vehicle; P = 0.054) or BQ-treated (BQ; P = 0.40) 5XFAD mice. (b) After the MWM test, 
the probe trials were performed in the same water pool in the absence of the scape platform. All images 
present the representative paths of the mice to search for the previous platform location [the small circle 
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area in the gray, northwest (NW) target quadrant] for 60 s (from point S to point E). (c-f) In the probe 
test, we recorded (c) the path distance to first enter the target quadrant, (d) the latency time to touch the 
previous location of the platform, (e) the crossing frequency to traverse across the target platform, and 
(f) the times spent in the target quadrant to search for the platform. Lanes: (WT) wild-type; (Vehicle) 
5XFAD + vehicle; (BQ) 5XFAD + BQ; (1) 5XFAD + 1. The statistical comparisons were performed 
between vehicle-treated 5XFAD and their wild-type littermate mice (∗) or between vehicle- and 1-
treated 5XFAD mice (#). Bars denote mean ± s.e.m. (animal numbers; n = 17 for wild-type mice; n = 
19 for vehicle-treated 5XFAD mice; n = 9 for BQ-treated 5XFAD mice; n = 12 for 1-treated 5XFAD 
mice). ∗,#P < 0.05, ∗∗,##P < 0.01, or ∗∗∗,###P < 0.001 by unpaired two-tail t-test. 
 
Figure 2.1. Fluorescent imaging of DHIC for Zn2+ with or without S2– in HeLa cells. (a) The cells were 
pre-incubated with DHIC for 1 h prior to treatment with Zn2+. (b) The cells incubated with DHIC for 
1 h were treated with Zn2+ for 1 h. Conditions: [DHIC] = 20 M; [Zn2+] = 600 M; [S2–] = 400 M; 
37 °C; 5% CO2. The scale bar is 50 m. 
 
Figure 2.2. Fluorescent imaging of ATA-DAS for Zn2+ in HeLa cells. The cells were incubated with 
ATA-DAS and Zn2+ for 10 min. Conditions: [ATA-DAS] = 30 M; [Zn2+] = 5 mM; 37 °C; 5% CO2. 
The scale bar is 50 m. 
 
Figure 2.3. Fluorescent imaging of TPH-Jul for Al3+ in HeLa cells. The cells were incubated with 
TPH-Jul with various concentrations of Al3+ for 2 h. Conditions: [TPH-Jul] = 10 M; [Al3+] = 0.25, 
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1.1. Introduction 
Generation of reactive oxygen species (ROS) is an inevitable consequence of cellular metabolism.1 
Intracellular ROS is tightly regulated through biological scavenging mechanisms utilizing a range of 
enzymes and antioxidants.1 Under normal conditions, in which the production and removal of ROS are 
balanced, ROS are involved in critical cellular processes, such as signal transduction and gene 
transcription.2-4 A shift in balance resulting in the overproduction of free radicals, however, can damage 
lipids, proteins, and DNA leading to oxidative stress.1,2,5  
The brain envelops a substantial amount of ROS as a product of the heightened O2 metabolism, 
high metal ion content, and deficient antioxidant capacity.6,7 At the cellular level, neurons exhibit an 
exceptional vulnerability against oxidative stress, which arises from its radical sensitive membrane and 
high membrane surface area to cytoplasmic volume ratio.8 Thus, oxidative stress is implicated as a 
central factor in the progression of neurodegeneration as observed in Alzheimer’s disease (AD), 
Parkinson’s disease, and amyotrophic lateral sclerosis.5,9-12 Clinical efforts to extensively prevent 
oxidative damage against AD employing natural antioxidants, including vitamin C and E, failed to 
demonstrate significant therapeutic efficacy in stopping the progress of the disease, however.13,14 Such 
observations have led researchers to recognize the complex multifactorial nature of AD.13,14 
Redox chemistry among pathogenic elements found in AD [e.g., ROS, amyloid- (A), and metal 
ions] denotes inter-connections among the proposed hypotheses regarding its etiopathology: oxidative 
stress, amyloid cascade, and metal ion.5,11,15-22 For instance, ROS are reported to promote the cerebral 
deposition of A, the aggregation-prone peptide constituent of senile plaques, by increasing its 
production and diminishing its degradation and clearance.23,24 In addition, ROS mediate A-induced 
neurotoxicity.15,25 Redox-active metal ions, highly accumulated in senile plaques of the AD-affected 
brain, can also generate ROS and coordinate to A peptides to form metal-bound A (metal–A) 
complexes that are also capable of forming ROS through Fenton-like reactions.5,11,22,26-28 
To advance our understanding of the pathological relationships among ROS, A, and metal ions, 
research efforts have been dedicated towards developing multifunctional chemical reagents that can 
target and regulate these pathogenic factors of AD.10,29-31 Numerous reports of multifunctional 
molecules presented a structure-based design strategy by linking, fusing, and incorporating previously 
published molecular frameworks exhibiting desired biological and chemical properties (e.g., 
antioxidant capacity, A interaction, and metal chelation).10,30,31 In contrast, a structure-mechanism-
based design strategy, which considers both chemical structures and mechanistic reactivity with targets, 
has been increasingly reported as a strategy to design multifunctional compounds, with the suggestion 
regarding a correlation between redox activity and multifunctionality.32-34 
Herein, we report compact molecules (Figure 1.1a), devised from the smallest aromatic backbone, 
benzene, with multi-reactivity against free radicals, metal-free A, and metal–A constructed through 
3 
a minimalistic redox-based design strategy. Only minor structural variations on benzene, including p-
substitution, were applied to tune its electronic properties. In addition, an inherent relationship between 
redox activity and multifunctionality was established and confirmed utilizing our series of strategically 
designed small molecules (1–10). The redox-active compounds (Group-I; Figure 1a, left) illustrated 
regulatory activities against free radicals, metal-free A, and metal–A in vitro. The representative 
molecule of the study, 1, further demonstrated its ability to reduce A accumulation and ameliorate 
cognitive deficits in vivo (Figure 1.1b). Our detailed mechanistic studies confirmed a redox-dependent 
trend regarding the molecules’ ability to interact and react with free radicals, metal-free A, and metal–
A. Collectively, the presented work validates the feasibility of converging multiple reactivities in a 
single structural entity by tuning the oxidation potential of a simple backbone through minor structural 
variations, without any structural complexity. In addition, our findings provide new insight towards 
designing multi-reactive chemicals and contribute towards the efficient and effective development of 




Figure 1.1. Overview of a rational strategy of designing small molecules targeting multiple pathogenic 
factors found in the AD-affected brain and the chemical series (Group-I and Group-II) studied in this 
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work. (a) Structures of Group-I (1–4) and Group-II (5–10) and the tendency of their oxidation 
potentials. 1, Benzene-1,4-diamine; 2, 4-aminophenol; 3, N1,N1,N4,N4-tetramethylbenzene-1,4-diamine; 
4, 4-(dimethylamino)phenol; 5, aniline; 6, 4-aminobenzoic acid; 7, pyridin-4-amine; 8, N,N-
dimethylaniline; 9, 4-(dimethylamino)benzoic acid; 10, N,N-dimethylpyridin-4-amine. (b) Summary of 
the multiple targets, desired in vitro activities, and in vivo efficacies.  
 
1.2. Results and Discussion 
1.2.1. Rational Design Principle and Redox Properties of Small Molecules with Multi-Reactivity 
Redox-active compounds have recently been reported for their utility as multifunctional small 
molecules capable of targeting and regulating more than one pathological factor implicated in the 
pathology of AD.32-35 This indicates the significance of redox property as a parameter for engineering 
such small molecules. This concept, however, has not been fully established. To validate this notion, 
ten compact molecules were rationally designed based on the benzene scaffold considering the 
correlation between redox activity and multi-reactivity against multiple pathological factors found in 
the AD-affected brain (i.e., free radicals, metal-free A, and metal–A). Benzene, the most basic 
aromatic structure, exhibits relative stability through its rigid sp2 hybrid structure.36-38 The structural 
symmetry of benzene affords a neutral molecular entity with marginal dipole moments influencing its 
electronic properties, making this molecule an ideal candidate for varying and examining the effects of 
its electronic distribution on benzene.39-41 Thus, we conducted various p-substitutions (i.e., 
incorporation of electron-donating or electron-withdrawing groups) onto benzene or replaced benzene 
with a heterocycle (i.e., pyridine) to build up two groups of small molecules (Group-I and Group-II; 
Figure 1.1a) and determine their oxidation potentials and multi-reactivity against free radicals, metal-
free A, and metal–A.  
Group-I (1–4), embodying a relatively electron-rich benzene, was specifically constructed to 
possess two electron-donating groups (e.g., primary amino, dimethyl amino, or hydroxyl group). In 
contrast, Group-II (5–10) was devised to exhibit a comparatively electron-poor aromatic structure by 
first introducing an electron-donating group (i.e., primary amino or dimethyl amino group) to afford 5 
and 8. Subsequent incorporation of an electron-withdrawing group (i.e., carboxylate group) yielded 6 
and 9, and replacement of benzene with pyridine produced 7 and 10. After procuring our library of 
compact molecules, their oxidation potentials, reactivity against multiple pathological factors of AD in 
vitro, and in vivo efficacy in an AD transgenic mouse model were determined (vide infra). 
The redox properties of Group-I and Group-II were evaluated by cyclic voltammetry (CV) in 
DMSO. Group-I exhibited quasi-reversible (1, 2, and 4) or reversible (3) redox potential waves 
(Figures 1.2a and 1.3 and Table 1.1). Oppositely, Group-II displayed irreversible redox potential waves 
(Figure 1.4 and Table 1.1). Therefore, the E1/2 values of the compounds could only be obtained from 
Group-I (1–4; ca. 0.14, 0.21, 0.21, and 0.069 V at 250 mV/s, respectively). Moreover, the first anode 
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potential (Epa1) of Group-I (1–4; ca. –0.096, 0.28, –0.054, and 0.20 V at 250 mV/s, respectively; Figure 
1.2b) was observed to be significantly lower than those of Group-II (5–10; ca. 0.68, 0.60, 0.71, 0.56, 
0.56, and 0.66 V at 250 mV/s, respectively; Figure 1.2b). Our CV data indicates that the compounds in 
Group-I undergo oxidation more readily than those in Group-II (Figure 1.2c), possibly due to the 
presence of two electron-donating groups promoting the stabilization of the cationic radical form 
through electron delocalization.40,42,43 Our studies confirm our design approach to alter the electronic 




Figure 1.2. Oxidation potentials of 1–10, measured by cyclic voltammetry. (a) Cyclic voltammograms 
of 1–4 in DMSO. (b) Values of the first oxidation potential (Epa1) and (c) order of oxidation potentials 
of 1–10 (scan rate at 250 mV/s; DMSO). Conditions: [compound] = 1 mM; [TBAPF6] = 0.1 M (for 
supporting electrolyte and reference electrode); [AgNO3] = 0.01 M (for reference electrode); N2 (g); 
scan rates = 25, 50, 100, 150, 200, and 250 mV/s; three electrodes: glassy carbon working electrode, 





Figure 1.3. Analysis of the cyclic voltammograms of 1–4. Plot of the current (ipa and ipc) as a function 
of (scan rate)1/2 (1/2), indicating the quasi-reversible couple of 1, 2, and 4 as well as the reversible 
couples of 3. Conditions: [compound] = 1 mM; [TBAPF6] = 0.1 M (for supporting electrolyte and 
reference electrode); [AgNO3] = 0.01 M (for reference electrode); N2 (g); scan rates = 25, 50, 100, 150, 
200, and 250 mV/s; three electrodes: glassy carbon working electrode, Ag/Ag(I) reference electrode, 




Figure 1.4. Cyclic voltammograms of 5–10 in DMSO. Conditions: [compound] = 1 mM; [TBAPF6] = 
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0.1 M (for supporting electrolyte and reference electrode); [AgNO3] = 0.01 M (for reference electrode); 
N2 (g); scan rates = 25, 50, 100, 150, 200, and 250 mV/s; three electrodes: glassy carbon working 
electrode, Ag/Ag(I) reference electrode, and platinum counter electrode; room temperature. 
 









1.2.2. Scavenging Capacity of 1–10 against Free Organic Radicals  
The Trolox equivalent antioxidant capacity (TEAC) assay32-35,44-47 was performed to measure the free 
radical scavenging ability of Group-I and Group-II. The cationic radical form of ABTS, ABTS•+ 
[ABTS = 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)], was used as a source of organic free 
radicals in the medium containing the lysates of murine neuroblastoma Neuro-2a (N2a) cells. The 
TEAC values represent the radical scavenging capacity of compounds relative to a water-soluble 
vitamin E analogue, Trolox.32-35,45,47 As shown in Figure 1.5, 1–4 (Group-I), observed to have lower 
oxidation potentials compared to those in Group-II, exhibited the substantial radical scavenge capacity 
comparable (1, 2, and 4) to or greater (3) than that of Trolox. The notable free radical scavenging activity 
of 3 might stem from the rapid kinetics of its oxidation and stabilization of its radical form.48,49 The 
antioxidant capacity of the compounds in Group-II could not be determined through the TEAC due to 
their limited radical scavenging activity. Overall, Group-I and Group-II demonstrate distinct 





Figure 1.5. Scavenging capability of compounds against free organic radicals, determined by the TEAC 
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assay employing cell lysates. The TEAC values are relative to that of an analog of vitamin E, Trolox 
(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). The error bars indicate the standard error 
from four independent experiments. ∗TEAC values of 5–10 were not obtained due to no measurable 
capacity to quench free radicals. 
 
1.2.3. Modulatory Effects of 1–10 towards Aggregation of Both Metal-free A and Metal–A. 
Aggregation and accumulation of A peptides, produced by enzymatic cleavages of amyloid precursor 
protein (APP), can induce neurotoxicity in the brain. Thus, A is considered as one of the pathogenic 
hallmarks of AD.15,17-20,50 In addition, binding of metal ions [e.g., Cu(II) and Zn(II)] to A can modify 
its aggregation pathways and also generate toxic A aggregates.51-54  Therefore, modulating those A 
aggregation pathways by small molecules is an efficient method for redirecting their on-pathways into 
less toxic, off-pathway.32,55,56 To identify the effects of 1–10 on the aggregation pathways of both metal-
free A and metal–A, the molecular weight (MW) distribution and morphology of the A aggregates, 
generated by treatment with our compounds, were analyzed through gel electrophoresis with Western 
blot (gel/Western blot) utilizing an anti-A antibody (6E10) and transmission electron microscopy 
(TEM), respectively (Figures 1.6-1.10). Inhibition (Figure 1.6a, 1.8a, and 1.10a) and disaggregation 
experiments (Figures 1.7a, 1.9a, and 1.10a) that can evaluate the compounds’ ability to inhibit the 
aggregation of A peptides or disassemble preformed A aggregates, respectively,30,32-35,47 were carried 
out employing A40 and A42, two major isoforms of A.15,18,20,34 Smaller A aggregates (ca. 1-240 kDa) 
can appear as dark smearing bands on the images of gel/Western blot. Conversely, larger A aggregates 
that are not able to penetrate the gel matrix are not observed via gel/Western blot. Such aggregates, 
however, are in general visualized through TEM. 
In the inhibition experiments with metal-free A40, 1–4 (in Group-I) noticeably increased the 
smearing bands from ca. 7 to 270 kDa or reduced the intensity of the bands at ca. < 7 kDa, compared 
to the compound-free A40 (Figure 1.6b). In the presence of metal ions [i.e., Cu(II) and Zn(II)], the 
change in the MW distributions of the A40 samples treated with 1–4 became more prominent (Figure 
1.6c,d). Oppositely, 5–10 (Group-II) did not discernibly alter the MW distributions of both metal-free 
A40 and metal–A40 (Figures 1.6b-d and 1.10b). TEM studies demonstrated deviant conformations of 
metal-free A40 and metal–A40 aggregates incubated with 1–4 from the gel/Western blot experiments. 
Small and truncated A40 fibrils, along with amorphous aggregates suggested to be less toxic than other 
structured aggregates,30,32,33 were observed from the samples of Group-I presenting a notable 
conformational contrast from the mature insoluble A40 fibrils produced from the samples of 





Figure 1.6. Effects of 1–5 on the formation of metal-free or metal-induced A40 aggregates. (a) Scheme 
of the inhibition experiments. (b-d) Gel/Western blots (an A antibody, 6E10) of the A40 species 
generated in the (b) absence and (c and d) presence of metal ions. Lanes: (C) A40; (1) A40 + 1; (2) 
A40 + 2; (3) A40 + 3; (4) A40 + 4; (5) A40 + 5. (e) TEM images of the samples obtained from (b) 
metal-free A40 and A40 with 1 equiv of (c) Cu(II) and (d) Zn(II). Conditions: [A40] = 25 M; [Cu(II) 
or Zn(II)] = 12.5, 25, and 50 M; [compound] = 50 M; 20 mM HEPES, pH 7.4 [for metal-free or 
Zn(II)-containing samples] or pH 6.6 [for Cu(II)-added samples], 150 mM NaCl; 37 °C; 24 h; constant 





Figure 1.7. Influence of 1–5 on preformed metal-free or metal-associated A40 aggregates. (a) Scheme 
of the disaggregation experiments. (b-d) Gel/Western blots (6E10) of the A40 species generated in the 
(b) absence and (c and d) presence of metal ions. Lanes: (C) A40; (1) A40 + 1; (2) A40 + 2; (3) A40 
+ 3; (4) A40 + 4; (5) A40 + 5. (e) TEM images of the samples obtained from (b) metal-free A40 and 
A40 with 1 equiv of (c) Cu(II) and (d) Zn(II). Conditions: [A40] = 25 M; [Cu(II) or Zn(II)] = 12.5, 
25, and 50 M; [compound] = 50 M; 20 mM HEPES, pH 7.4 [for metal-free or Zn(II)-containing 
samples] or pH 6.6 [for Cu(II)-added samples], 150 mM NaCl; 37 °C; 24 h; constant agitation. Scale 




Figure 1.8. Impact of 1–5 on formation of metal-free or metal-induced A42 aggregates. (a) Scheme of 
the inhibition experiments. (b-d) Gel/Western blots (6E10) of the A42 species generated in the (b) 
absence and (c and d) presence of metal ions. Lanes: (C) A42; (1) A42 + 1; (2) A42 + 2; (3) A42 + 3; 
(4) A42 + 4; (5) A42 + 5. (e) TEM images of the samples obtained from (b) metal-free A42 and A42 
with 1 equiv of (c) Cu(II) and (d) Zn(II). Conditions: [A42] = 25 M; [Cu(II) or Zn(II)] = 12.5, 25, and 
50 M; [compound] = 50 M; 20 mM HEPES, pH 7.4 [for metal-free or Zn(II)-containing samples] or 





Figure 1.9. Influence of 1–5 on preformed metal-free or metal-induced A42 aggregates. (a) Scheme of 
the disaggregation experiments. (b-d) Gel/Western blots (6E10) of the A42 species generated in the (b) 
absence and (c and d) presence of metal ions. Lanes: (C) A42; (1) A42 + 1; (2) A42 + 2; (3) A42 + 3; 
(4) A42 + 4; (5) A42 + 5. (e) TEM images of the samples obtained from (b) metal-free A42 and A42 
with 1 equiv of (c) Cu(II) and (d) Zn(II). Conditions: [A42] = 25 M; [Cu(II) or Zn(II)] = 12.5, 25, and 
50 M; [compound] = 50 M; 20 mM HEPES, pH 7.4 [for metal-free or Zn(II)-containing samples] or 





Figure 1.10. Effects of 6–10 on metal-free or metal-induced A40 and A42 aggregation pathways. (a) 
Scheme of the inhibition and disaggregation experiments. (b and c) Analysis of the resultant (b) A40 
and (c) A42 species by gel/Western blot (6E10). Lanes: (C) A40/42; (6) A40/42 + 6; (7) A40/42 + 7; (8) 
A40/42 + 8; (9) A40/42 + 9; (10) A40/42 + 10. Conditions: [A40/42] = 25 M; [Cu(II) or Zn(II)] = 25 M; 
[compound] = 50 M; 20 mM HEPES, pH 7.4 [for metal-free or Zn(II)-containing samples] or pH 6.6 
[for Cu(II)-added samples], 150 mM NaCl; 37 °C; 24 h; constant agitation. 
 
The A40 disaggregation experiments (Figure 1.7) presented similar trends to those of the 
inhibition experiments. The compounds in Group-I altered the MW distribution of metal-free A40 and 
metal–A40 samples and their aggregate morphologies (Figure 1.7b-e), while the molecules in Group-
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II did not exhibit such perceivable reactivity (Figures 1.7b-e and 1.10b). As depicted in Both inhibition 
and disaggregation experiments of A42 (Figures 1.8b-e, 1.9b-e, and 1.10c) indicated the similar results 
of the A40 studies. Our gel/Western blot and TEM data illustrated that the compounds in Group-I, 
designed to possess two electron-donating groups at the p-position on benzene, could modulate the 
formation of metal-free A and metal–A aggregates and disassemble the corresponding preformed 
aggregates. Furthermore, the contrasting lack of reactivity from the compounds in Group-II, 
embodying a less electron-dense benzene, implies a correlation between our molecules’ oxidation 
potentials and their ability to interact with metal-free A and metal–A and redirect their aggregation 
pathways.  
 
1.2.4. Oxidative Transformation of 1–10 in the Absence and Presence of A and Metal Ions 
To understand the distinction in the modulative reactivity of the molecules towards the aggregation of 
metal-free A and metal–A with respect to their redox properties, the chemical transformations of 
Group-I and Group-II were monitored in solution via UV–Vis spectroscopy under various conditions: 
with or without A40 in both the absence and presence of metal ions [e.g., Cu(II) or Zn(II); Figures 1.11a 
and 1.12]. In the absence of A40 and metal ions, 1’s optical spectrum exhibited an increase in absorption 
at ca. 530 nm resulting in the appearance of a broadband (Figure 1.12a, bottom), indicative of 1’s 
transformation to an intermediate cationic radical and subsequent dimerization and trimerization of the 
cationic radicals.57-59 The hypsochromic shift from ca. 300 to 250 nm implies the oxidative 
transformation of 1 to p-benzoquinonediimine (BQDI) or p-benzoquinone (BQ).58,60 Addition of redox-
active Cu(II) accelerated the oxidative transformation of 1, reaching the maximum absorption in 4 h (at 
ca. 530 nm), while the introduction of Zn(II), a redox-inactive metal, did not noticeably alter the 
transformation kinetics (Figure 1.12a, bottom). 
Notable optical changes of 1 were observed upon treatment of A40 with and without metal ions 
(Figures 1.11a and 1.12a, top). Under metal-free and Zn(II) conditions, absorbance at ca. 250 and 350 
nm first gradually increased and decreased with time, respectively, indicating the transformation of 1 to 
BQDI or BQ.58,60 The subsequent alterations of the peak intensity at ca. 250 nm (decrease) and ca. 350 
nm (increase) denote 1’s covalent interaction with A40.32 In the presence of Cu(II) with A40, the optical 
spectra of 1 exhibited several distinct optical changes: (i) a significant sequential increase and decrease 
of the absorption band at ca. 250 nm; (ii) band intensification at ca. 350 nm, noticeably larger compared 
to those shown under metal-free and Zn(II)-present conditions; (iii) absence of the broad peak at ca. 
500 nm, present under metal-free conditions, interpreted as a considerable decrease in the dimerization 
or trimerization of 1, as a consequence of the fast and vigorous oxidation of 1 to BQ in the presence of 
Cu(II), followed by the covalent adduct formation of BQ with A40 species (Figure 1.11a, bottom). 
In addition to 1, the other compounds in Group-II, 2–4 were optically analyzed in the absence 
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and presence of A40 with or without metal ions. Under the absence of A40 conditions, the oxidative 
transformation of each compound was observed as previously reported (Figure 1.12b-d).57,59,61-63 When 
the compounds were incubated with A40, the optical spectra showed that 2–4 were able to undergo 
oxidative transformation to BQ to form covalent bonds with A40, except for that of compound 3 due 
to substantial interference from 3’s radical species (Figure 1.12b-d).57,59,62 In contrast to the optical 
changes of the compounds in Group-I, the molecules in Group-II did not present perceivable spectral 
alterations throughout the measurement period under all conditions (Figure 1.12e-j). This bimodal trend 
suggests that a low oxidation potential is critical for undergoing the oxidative transformation of 
compounds to yield products (i.e., BQ) capable of interacting with both metal-free A and metal–A. 
Collectively, our spectral data reveal the molecular mechanism conducive to the underlying interactions 





Figure 1.11. Analyses of 1’s transformation and interaction with metal-free A40 or Cu(II)-associated 
A40 as well as proposed mechanisms. (a) Transfiguration of 1 in the presence of A40 with or without 
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Cu(II), detected by UV–Vis spectroscopy. Conditions: [A40] = 25 M; [Cu(II)] = 25 M; [1] = 50 M; 
20 mM HEPES, pH 7.4 (for metal-free samples) or pH 6.6 [for Cu(II)-added samples], 150 mM NaCl; 
37 °C; 0-24 h; no agitation. (b-d) Interactions of 1 with metal-free A40 and Cu(II)-treated A40, 
analyzed by ESI–MS, ESI–MS2, and MALDI–MS. A40 monomer incubated with 1 in the (b and d) 
absence and (d) presence of Cu(II) was detected by (b) ESI–MS or (d) MALDI–MS. Oxidized A40 and 
an adduct between A40 and oxidatively transformed 1 (i.e., BQ) are indicated with red and blue circles, 
respectively. The covalent bond with A40 (green circle) was only observed from 1-treated samples. (c) 
ESI–MS2 spectrum of the singly oxidized A404+ produced upon addition of 1. Conditions (for ESI–MS 
studies): [A40] = 50 M; [1] = 100 M; 1 mM ammonium acetate, pH 7.4; 37 °C; 24 h; no agitation. 
The samples were diluted by 10 fold with ddH2O before injection to the mass spectrometer. Conditions 
(for MALDI–MS measurements): [A40] = 25 M; [Cu(II)] = 25 M; [1] = 50 M; pH 7.4 (for metal-
free samples) or pH 6.6 [for Cu(II)-added samples]; 37 °C; 24 h; constant agitation. (e) Two proposed 
pathways: (left) peptide oxidation by 1; (right) Formation of a covalent adduct between A and 


















Figure 1.12. Transformation of 1–10 in the absence and presence of A40 with or without metal ions, 
detected by UV–Vis spectroscopy. Conditions: [A40] = 25 M; [Cu(II) or Zn(II)] = 25 M; [compound] 
= 50 M; 20 mM HEPES, pH 7.4 [for metal-free or Zn(II)-containing samples] or pH 6.6 [for Cu(II)-
added samples], 150 mM NaCl; 37 °C; 0-24 h; no agitation.  
 
1.2.5. Interactions of 1–5 with Metal-free A or Metal–A 
Predicted interactions between our compounds, 1–5, and A40 were first visualized by employing a 
previously reported NMR structure of an A40 monomer (PDB 2LFM)64 and AutoDoc Vina. Simulations 
showed that 1–5 were situated in a pocket near the self-recognition site (Figure 1.13a). The binding 
energy of these interaction was calculated to range from –4.7 to –4.0 kcal/mol (Figure 1.13b). Based on 
these results and referring back to our in vitro experiments (gel/Western blot and UV–Vis spectroscopy), 
in which only 1–4 exhibited the modulatory reactivity towards metal-free A40 aggregation, we propose 
that the redox potential of these compounds is a key factor for the capacity for interacting with A and 






Figure 1.13. Docking studies of 1–5 with A40 monomer (PDB 2LFM). (a) Docked conformations of 
compounds with A40 (surface and zoon-in images). Hydrogen bonding between compounds and A40 
is indicated with gray dashed lines (2.2-2.7 Å). The self-recognition site in A40 is highlighted in yellow. 
(b) Binding energy of the compounds with A40 monomer. 
 
To identify the direct interactions between 1–5 and metal-free A40 or metal–A40 at the 
molecular level, two types of mass spectrometry [i.e., electrospray ionization mass spectrometry (ESI–
MS) and matrix-assisted laser desorption/ionization mass spectrometry (MALDI–MS)] were employed. 
ESI–MS studies were first conducted with the samples to verify the underlying mechanisms responsible 
for the modulating effects of 1–5 against metal-free A40 aggregation. The control experiments led to 
the detection of a peak at 1083 (or 1444) m/z corresponding to the +4 (or +3)-charged A40 monomer, 
respectively (Figures 1.11b and 1.14a). In the presence of the more redox-active molecules,1–4 (Group-
I), the addition of 104 Da to the +4 (or +3)-charged-A40 monomer [i.e., covalent adduct formation with 





Figure 1.14. Interactions of 1–5 with metal-free and metal-treated A40. A40 monomer incubated (a) 
with 2–5 in the absence of metal ions and (b) with 1 in presence of Zn(II) was monitored by (a) ESI–
MS and (b) MALDI–MS. Oxidized ions of A40 and A40–BQ adducts are indicated with red and blue 
circles, respectively. The covalent adducts between A40 and oxidatively transformed 1–4 (i.e., BQ) are 
indicated with green circles. Conditions (for ESI–MS studies): [A40] = 50 M; [compound] = 100 M; 
1 mM ammonium acetate, pH 7.4; 37 °C; 24 h; no agitation. The samples were diluted by 10 fold with 
ddH2O before injection to the mass spectrometer. Conditions (for MALDI–MS measurements): [A40] 
= 25 M; [Zn(II)] = 25 M; [1] = 50 M; pH 7.4; 37 °C; 24 h; constant agitation. 
 
Peaks signifying the oxidation of A40, ca. 1087 m/z for [A40 + O + 4H]4+ or 1449 m/z for [A40 
+ O + 3H]3+, were also detected in the compound-treated samples of metal-free A40 (red circles; Figures 
1.11b and 1.14a). Furthermore, new peaks (ca. 1113 [A40 + O + 104 + 4H]4+ or 1484 [A40 + O + 104 
+ 3H]3+ m/z), indicating the oxidized species of the covalent adduct (BQ–A40), were detected when 
metal-free A40 was treated with Group-I (blue circles; Figures 1.11b and 1.14a). Previous studies 
regarding the A oxidation mechanism proposed that ROS, such as superoxide anion (O2•–) or hydrogen 
peroxide (H2O2), possibly generated through the redox cycle65 with Group-I, could oxidize A and 
consequently modulate A aggregation.66-70 Tandem MS (ESI–MS2) studies were carried out to 
determine the oxidation sites of the [A40 + O + 4H]4+ species (1087 m/z; red dot; Figure 1.11b) in the 
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presence of 1, a representative of Group-I. Fragmental analysis of this peak, through collision-induced 
dissociation (CID), implicated His14 and Met35 as possible oxidation sites (Figure 1.11c), yielding 2-
oxohistidine and methionine sulfoxide, respectively.16,71 Interactions between 5 and A40 were identified 
as a representative study of Group-II, which did not exhibit significant reactivity towards metal-free 
A and metal–A in the experiments through gel/Western blot and UV–Vis spectroscopy (Figures 1.6-
1.9, and 1.12e). Contrasting from the samples treated with the molecules in Group-I, ESI–MS analysis 
of the 5-added A40 samples did not show the peaks corresponding to the covalent adduct with A40 or 
oxidized A40 (Figure 1.14a). 
MALDI––MS was conducted to further investigate the interactions of 1 with metal-free A40 and 
metal–A40. Upon addition of 1 to the metal-free A40 samples, a new peak at 4436 m/z (i.e., [A40 + 
104 + H]+) was detected, indicative of a covalent adduct of the oxidatively transformed 1, BQ, with the 
A40 monomer (Figure 1.11d). The covalent adduct formation was also detected in the presence of metal 
ions [i.e., Cu(II) or Zn(II)] (Figures 1.11d and 1.14b). In the samples of Cu(II)–A40, new peaks 
corresponding to the addition of one or two oxygen atoms to A40 monomer (at 4348 and 4364 m/z) or 
BQ–A40 adducts (at 4452 and 4468 m/z) were observed, as in the ESI–MS analysis of the metal-free 
A40 samples incubated with Group-I (Figure 1.11d). 
The presented MS data provide the mechanistic details of Group-I’s modulative reactivity 
towards the aggregation of both metal-free A and metal–A: covalent adduct formation and peptide 
oxidation. Both proposed mechanisms are strongly dependent on the redox properties of the molecules, 
since the oxidative transformation of Group-I is responsible for generating the covalent adducts (BQ) 
to A and ROS (e.g., O2•– and H2O2), as byproducts capable of inducing the oxidation of A.65,72 
Together, our spectrometric observations support the significance of redox properties as a critical design 
parameter for molecules with multi-reactivity against metal-free A and metal–A. The distinct 
reactivities between Group-I and Group-II, observed via gel/Western blot, UV–Vis spectroscopy, and 
spectrometric studies, corroborate our redox-based design principle for multi-reactivity 
 
1.2.6. Bioapplicability of 1–4 
The bioapplicability (e.g., cell viability, metabolic stability, and brain uptake) of Group-I was assessed 
prior to in vivo studies. First, cytotoxicity of 1–4 was determined in N2a cells through the MTT assay. 
N2a cells were treated with 1–4 at a range of concentrations (from 5 to 50 M) for 24 h. Cells incubated 
with 1 showed ca. 80% viability at 50 M. In contrast, cells exhibited ca. 70, 70, and 50% viability 
upon treatment with 2, 3, and 4, respectively, at the same concentration (Figure 1.15). Second, the half-
life (t1/2) and intrinsic clearance (CIint) of 1–4, which are representative indicators for microsomal 
degradation of the molecules, were monitored as a measure of their metabolic stability. 1, 2, and 4 
presented t1/2 greater than 60 min and CIint ca. 20 mL/min/mg, indicating their relatively metabolic 
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stability (Table 1.2). 3, on the other hand, presented poor metabolic stability in comparison (74 
mL/min/mg protein). Lastly, the blood-brain barrier (BBB) permeability of 1, the least toxic and most 
metabolically stable candidate, was examined in vivo. Detection of 1 in the brains of CD1 mice, 
following oral administration (10 mg/kg), denoted the molecule’s ability to cross the BBB (Table 1.3). 
Our evaluations of Group-I’s bioapplicability prompted 1 as a suitable candidate for further 




Figure 1.15. Cytotoxicity of 1–4. Cell viability (%) of N2a cells incubated with various concentrations 
of 1–4 was obtained by the MTT assay. Error bars indicate the standard error from four independent 
experiments. Conditions: [compound] = 5, 10, 25, and 50 M (1 % v/v DMSO); 37 °C; 24 h. 
 




bintrinsic clearance (Clint). 
 
Table 1.3. Concentrations of 1 in plasma, brain, and cerebrospinal fluid (CSF) after its 5 min 




aMean (n = 3); bstandard deviation; ccoefficient of variation. 
 
1.2.7. In Vivo Efficacies of 1 and BQ towards A Accumulation and Cognitive Function in 5XFAD 
Mice 
Based on its in vitro multi-reactivity and bioapplicability, 1 was selected as a representative molecule 
from Group-I, along with BQ, the final product of 1’s oxidative transformation, as the chemical 
subjects of our in vivo studies regarding their in vivo efficacies in a transgenic AD murine model (i.e., 
5XFAD mice). 5XFAD is an AD transgenic mouse model overexpressing mutant human APP695 
[Swedish (K670N/M671L), Florida (1716V), and London (V7171)] along with PS1 (M146L and 
L286V), inducing the rapid A42 production and onset of AD pathology.32,33,73 First, the weight, physical 
appearance, and behavior of the mice were carefully examined every day for the duration of the 
compound administration. In comparison with the vehicle- and 1-treated (1 mg/kg/day; i.p.) groups, 
which showed 0% (no death of 19 mice tested) and 14% (2 deaths of 14 mice) mortality, respectively, 
BQ-treated (1 mg/kg/day; i.p.) mice exhibited higher mortality rates (40%; 6 deaths of 15 mice). BQ 
treatment resulted in perceivable decreases (in males) and slight increases (in females) in weight among 
the survivors, whereas administration of vehicle and 1 yielded a general increase in weight (Table S4). 
Furthermore, BQ-treated 5XFAD mice manifested hypomotility and reduced task performance capacity 
relative to the vehicle- or 1-treated 5XFAD mice (data not shown). Gross murine necropsy revealed the 
abnormal morphology of intraperitoneal organs including lesions at the injection site and severe internal 
adhesions accompanied by chronic inflammation in a majority of BQ-treated 5XFAD mice; such 
detriments were not observed in the vehicle- or 1-treated mice (data not shown). Long-term i.p. 
administration of BQ induced significant toxicity in 5XFAD mice at 1 mg/kg/day and, at times, resulted 
in the termination of the test subject. In contrast, 1 (1 mg/kg/day) was sufficiently tolerated by 5XFAD 
mice throughout the repeated administration periods, reinforcing its in vivo safety. 
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Table 1.4. Change in the body weights of 5XFAD mice during the 30-repeated administrations of 1 and 
BQ [1 mg/kg/day; intraperitoneal (i.p.) injection]. 
 
 
aMean ± s.e.m. (animal number). 
 
Despite BQ’s prominent toxicity, the effects of 1 and BQ on amyloid deposition in the brains of 
5XFAD mice were evaluated in the surviving population of test subjects (n = 12 of 14 mice and 9 of 15 
mice for 1 and BQ, respectively). Enzyme-linked immunosorbent assay (ELISA) indicated the 
noticeable reduction in the levels of soluble [phosphate buffered saline (PBS)- and sodium dodecyl 
sulfate (SDS)-soluble fractions], insoluble [formic acid (FA)-soluble fractions], total (sum of PBS-, 
SDS-, and FA-soluble fractions) A42, and oligomeric A species in the brains of BQ-treated 5XFAD 
mice, relative to those of vehicle-treated 5XFAD mice (20%, 7.4%, 15%, and 26% decrease, 
respectively); these differences, however, were not deemed statistically significant (Figure 1.16a). 4G8-
immunohistochemical evaluations exhibited BQ-induced reduction in the levels of amyloid deposits 
(31%) with borderline statistical significance. Additionally, BQ was only able to decrease the deposition 
of compact congophilic amyloid plaques by 7.2% (Figure 1.16b,c). It should be noted that BQ’s toxicity 
likely poses a potential interference to the in vivo evaluation regarding the molecule’s ability to curb 
the A pathology in 5XFAD mice. Additional studies are warranted to elucidate the dose-dependent 






Figure 1.16. Analysis of the amounts of A species in 1- or BQ-treated 5XFAD mice. (a) Levels of 
soluble A42, insoluble A42, total A42, and oligomeric A were analyzed in triplicate per sample by 
ELISA. Lanes: (Vehicle) 5XFAD + vehicle; (BQ) 5XFAD + BQ; (1) 5XFAD + 1. (b) Loads of amyloid 
deposits and plaques in the brain expressed as the percent area of 4G8-immunoreactive deposits or the 
number of congophilic plaques per mm2 of a region of interest, which was taken from hippocampal 
(hip), cortical (ctx) and thalamic (tlm) areas. (c) Representative images of 4G8-immunoreactive (1st row) 
or Congo red-positive (2nd and 3rd rows) amyloid deposits or plaques in hip and ctx (1st and 3rd rows), 
or tlm (2nd row) regions in the brains of vehicle- (1st column), BQ- (2nd column), or 1-treated (3rd column) 
5XFAD mice are shown. Congo red stained brain sections were also counter-stained with haematoxylin 
to differentiate the nuclei of neural cells (2nd and 3rd rows). Subiculum (sub), corpus callosum (cc), and 
fornix (fx). Scale bars = 500 m (white) or 200 m (black). The measurements were performed in five 
sagittal sections taken every 200 m from midline per animal. Bars denote mean ± standard errors of 
mean (s.e.m.) (animal numbers; n = 19 for vehicle-treated 5XFAD mice; n = 9 for BQ-treated 5XFAD 
mice; n = 12 for 1-treated 5XFAD mice). ∗P < 0.05, or ∗∗P < 0.01 by unpaired two-tail t-test. 
 
In contract, 1 prominently attenuated the amyloid pathology in the brains of 5XFAD mice. All 
fractions of A42, analyzed (soluble, insoluble, and total A42) and oligomeric A from the 1-treated 
mice, were significantly reduced in comparison with the vehicle-treated 5XFAD mice (28%, 27%, 28%, 
and 28%, respectively; Figure 1.16a). 1 also diminished the deposition of 4G8-immunoreactive amyloid 
aggregates and compact congophilic amyloid plaques (28% and 17%, respectively; Figure 1.16b,c). 
Moreover, the repeated administration of 1 significantly improved the cognitive performance of 5XFAD 
mice. During the 5 day trial period of the Morris water maze (MWM) test, 1-treated 5XFAD mice found 
the escape platform more easily and quickly relative to the vehicle- or BQ-treated 5XFAD mice (Figure 
1.17a), showing that the treatment of 1 improved their spatial learning ability. In the subsequent probe 
test, which examines the long-term spatial memory of the mice, we found that 1-treated 5XFAD mice 
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took shorter paths to the target zone (Figure 1.17b,c) and less time to reach the target location (Figure 
1.17d), more frequently traversed the target location (Figure 1.17e), and spent more time in the target 
quadrant (Figure 1.17b,f). These results prove that 1 could effectively improve the spatial learning and 
memory of 5XFAD mice. Overall, our comparative in vivo evaluation of 1 and BQ demonstrate that 
although both molecules were able to reduce the cerebral and hippocampal A load, 1 exhibited 
significantly lower toxicity and was much more efficient in reducing the A pathology and recovering 




Figure 1.17. Measurement of spatial learning and memory improvements in 1- or BQ-administrated 
5XFAD mice. (a) Escape latency time daily assessed for five days from the day of the 30th compound 
treatment in the Morris water maze (MWM) test. From the 2nd training trial to the 5th trial, the latency 
time became significantly shorter in non-transgenic wild-type mice (WT; P = 0.012 by one-way 
ANOVA with Student-Newman-Keuls post hoc test) or 1-treated 5XFAD mice (1; P = 0.0017), but not 
in vehicle- (Vehicle; P = 0.054) or BQ-treated (BQ; P = 0.40) 5XFAD mice. (b) After the MWM test, 
the probe trials were performed in the same water pool in the absence of the scape platform. All images 
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present the representative paths of the mice to search for the previous platform location [the small circle 
area in the gray, northwest (NW) target quadrant] for 60 s (from point S to point E). (c-f) In the probe 
test, we recorded (c) the path distance to first enter the target quadrant, (d) the latency time to touch the 
previous location of the platform, (e) the crossing frequency to traverse across the target platform, and 
(f) the times spent in the target quadrant to search for the platform. Lanes: (WT) wild-type; (Vehicle) 
5XFAD + vehicle; (BQ) 5XFAD + BQ; (1) 5XFAD + 1. The statistical comparisons were performed 
between vehicle-treated 5XFAD and their wild-type littermate mice (∗) or between vehicle- and 1-
treated 5XFAD mice (#). Bars denote mean ± s.e.m. (animal numbers; n = 17 for wild-type mice; n = 
19 for vehicle-treated 5XFAD mice; n = 9 for BQ-treated 5XFAD mice; n = 12 for 1-treated 5XFAD 
mice). ∗,#P < 0.05, ∗∗,##P < 0.01, or ∗∗∗,###P < 0.001 by unpaired two-tail t-test. 
 
1.3. Conclusion 
Difficulty in understanding the pathology of AD stems from its multifactorial nature. Ensuing 
inadequacy in comprehending the causes of neurodegeneration in AD severely impedes the 
development of therapeutics capable of halting the progression of the disease. To advance our 
understanding of AD pathology and discover effective therapeutics, small molecules capable of 
targeting multiple pathogenic factors have been designed as both investigative chemical tools and 
potential therapeutics. As a recently emerging concept, the structure-mechanism-based molecular 
design has presented the feasibility of controlling a molecule’s reactivity towards various pathological 
factors of AD by tuning its electronic property. To consolidate this design strategy, we rationally devised 
compact molecules based on the simplest aromatic framework, benzene, by adjusting its electronic 
distribution to impart redox-dependent multi-reactivity against the pathological factors of AD (i.e., free 
radicals, metal-free A, and metal–A). The molecules were classified into two groups: Group-I (1–4; 
incorporation of two electron-donating groups at the p-position onto benzene) and Group-II (5–10; 
containing an electron-donating group and additional structural modifications with electronic 
implications). Our biochemical and biophysical studies demonstrated the redox-dependent multi-
reactivity of Group-I towards free radicals, metal-free A, and metal–A. Further spectroscopic and 
spectrometric results elucidated the mechanisms involved in the regulatory effects of Group-I against 
A: covalent adduct formations and peptide oxidations. As a candidate molecule with favorable 
bioapplicability (e.g., low cytotoxicity, moderate metabolic stability, and potential BBB permeability), 
1 induced a significant reduction of cerebral and hippocampal A deposits and produced statistically 
significant improvements in the cognitive function of 5XFAD mice. Taken together, our 
multidisciplinary studies establish and validate redox activity as a critical parameter to consider when 
designing compounds with multi-reactivity as observed through our redox-based design strategy of 
modifying the electronic properties of benzene. These studies can be helpful in understanding the 
uncovered relationships between the intertwined pathogenic factors and contribute towards efficiently 
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finding effective chemical reagents against AD. 
 
1.4. Experimental Section 
1.4.1. Materials and Methods 
All chemical reagents were purchased from commercial suppliers and used as received unless otherwise 
stated. Benzene-1,4-diamine (1), 4-aminophenol (2), and 4-(dimethylamino)benzoic acid (9) were 
obtained from TCI (Chuo-ku, Tokyo, Japan). N1,N1,N4,N4-Tetramethylbenzene-1,4-diamine (3), aniline 
(5), 4-aminobenzoic acid (6), pyridin-4-amine (7), N,N-dimethylaniline (8), and N,N-dimethylpyridin-
4-amine (10) were gained from Alfa Aesar (Ward Hill, MA, USA). 4-(Dimethylamino)phenol (4) was 
bought from Ark Pharm, Inc. (Arlington Heights, IL, USA). p-Benzoquinone (BQ) was gained from 
Sigma-Aldrich (St. Louis, MO, USA). A40 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGL-
MVGGVV) and A42 (DAEFRHDSGYEV-HHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) were 
purchased from Anaspec (Fremont, CA, USA). HEPES (2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid) was purchased from Sigma-Aldrich. The buffered solution was prepared in 
doubly distilled water [ddH2O; a Milli-Q Direct 16 system (18.2 Mcm; Merck KGaA, Darmstadt, 
Germany)]. Trace metal contamination was removed from the solutions used for the experiments by 
treating with Chelex (Sigma-Aldrich) overnight. Oxidation potentials of compounds were measured by 
a CHI620E potentiostat (CH Instruments, Inc., Bee Cave, TX, USA). Absorbance values obtained by 
the Trolox equivalent antioxidant capacity (TEAC) and MTT assays were determined by a SpectraMax 
M5e microplate reader (Molecular Devices, San Jose, CA, USA). Results obtained by gel 
electrophoresis with Western blotting (gel/Western blot) were visualized by a ChemiDoc MP imaging 
system (Bio-Rad, Hercules, CA, USA). Transmission Electron Microscopical images were acquired by 
a JEOL JEM-2100 transmission electron microscope [UNIST Central Research Facilities (UCRF), 
UNIST, Ulsan, Republic of Korea]. Docking studies of compounds with A40 monomer were carried 
out by AutoDock Vina 1.5.6 software. Optical spectra were recorded on an Agilent 8453 UV–Vis 
spectroscopy (Santa Clara, CA, USA). Mass spectra for examining the interactions of 1 and 3–5 with 
A40 in the absence and presence of Cu(II) or Zn(II) were taken on an Ultraflex III time-of-flight mass 
spectrometer (UCRF) or a Synapt G2-SI mass spectrometer [Daegu Gyeongbuk Institute of Science 
and Technology (DGIST) Center for Core Research Facilities (CCRF), DGIST, Daegu, Republic of 
Korea]. Metabolic stability to predict the half-life and clearance of compounds was evaluated with 
human liver microsomes [Daegu Gyeongbuk Medical Innovation Foundation (DGMIF), Daegu, 
Republic of Korea]. Analysis of the brain uptake of 1 in male CD1 mice was implemented at Shanghai 
ChemPartner (Shanghai, China). 
 
1.4.2. Cyclic Voltammetry 
Cyclic voltammograms were recorded under N2 (g) with a CHI620E potentiostat (CH Instruments, Inc.) 
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and three electrodes composed of a glassy carbon working electrode (ALS Co., Ltd, Tokyo, Japan), an 
Ag/Ag(I) reference electrode (RE-7 non-aqueous reference electrode; ALS Co., Ltd), and a Pt wire 
auxiliary electrode (ALS Co., Ltd). Oxidation potentials of compounds (dissolved in DMSO; final 
concentration of 1 mM) were recorded in DMSO containing tetrabutylammonium hexafluorophosphate 
(TBAPF6; 0.1 M) with the Ag/Ag(I) reference filled with the mixture (0.1 M TBAPF6 and 0.01 M 
AgNO3) at various scan rates (25, 50, 100, 150, 200, and 250 mV/s) at room temperature. 
 
1.4.3. Trolox Equivalent Antioxidant Capacity (TEAC) Assay 
The TEAC assay employing lysates of murine neuroblastoma Neuro-2a (N2a) cells [American Type 
Cell Collection (ATCC), Manassas, VA, USA] was conducted following the previously reported 
methods.30,47 Cell lysates were prepared following a previously reported procedure with modifications.74 
The N2a cells were seeded in a six-well plate and grown to approximately 80-90% confluence. Cells 
were washed once with cold phosphate buffered saline (PBS, pH 7.4; GIBCO, Grand Island, NY, USA) 
and harvested by gently pipetting off adherent cells with cold PBS. The cell pellet was generated by 
centrifugation (2,000 g for 10 min at 4 °C) and sonicated on ice (5 s pulses, three times with 20 s 
intervals between each pulse) in 2 mL of cold buffer (5 mM potassium phosphate, pH 7.4, containing 
0.9% NaCl and 0.1% glucose). The cell lysates were centrifuged at 5,000 g for 10 min at 4 °C. The 
supernatant was removed and stored on ice until use. To prepare the standard and samples in 96 well 
plates, 10 L of the supernatant of cell lysates was delivered followed by the addition of metmyoglobin 
(10 L, 55 M; Sigma-Aldrich), 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS; 150 
L, 220 M; Sigma-Aldrich), compound (10 L), and H2O2 (40 L, 412 M) in order. Compounds 
concentration ranges utilized were as follows: Trolox, 1 and 2 (45, 90, 135, 180, 225, and 330 M); 4 
(50, 100, 150, 200, 250, and 300 M); 3 (20, 40, 60, 80, 100, 120, and 140 M). The absorbance values 
were recorded at 750 nm. The percent inhibition was calculated according to the measured absorbance 
[% inhibition = 100 x (A0 – A)/A0, where A and A0 are the absorbance of the supernatant of cell lysates 
with and without compounds treatment, respectively] and was plotted as a function of a compound 
concentration. The TEAC values of compounds for each time point were calculated as a ratio of the 
slope of a compound to that of Trolox. The measurements were conducted in quadruplicate. 
 
1.4.4. A Aggregation Experiments 
A was dissolved in ammonium hydroxide [NH4OH (aq), 1% v/v]. The resulting solution was aliquoted, 
lyophilized overnight, and stored at –80 °C. A stock solution of A was then prepared by dissolving the 
lyophilized peptide using NH4OH (aq) (10 L, 1% v/v) and diluting with ddH2O. All A samples were 
prepared following the previously reported procedures.30,32,75,76 The concentration of the peptide 
solution was determined by measuring the absorbance of the solution at 280 nm ( = 1,450 M–1cm–1 for 
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A40;  = 1,490 M–1cm–1 for A42). The buffered solution (20 mM HEPES, pH 7.4, 150 mM NaCl) was 
used for the preparation of A samples. For the inhibition studies, compounds (final concentration, 50 
M; 1% v/v DMSO) were added to the samples of A (25 M) in the absence and presence of metal 
ions [Cu(II) or Zn(II); 25 M] followed by incubation for 24 h at 37 °C with constant agitation. For the 
disaggregation studies, A (25 M) was incubated with and without metal ions [Cu(II) or Zn(II); 25 
M] for 24 h at 37 °C with constant agitation to generate preformed A aggregates. The resulting A 
aggregates were then treated with compounds (50 M) and incubated for an additional 24 h with 
constant agitation. 
 
1.4.5. Gel Electrophoresis with Western Blotting (Gel/Western blot) 
The resultant A species from in vitro experiments were analyzed through gel/Western blot using an 
anti-A antibody (6E10).30,32,75,76 The samples (10 L) were separated on a 10-20% Tris-tricine gel 
(Invitrogen, Carlsbad, CA, USA). Following separation, the proteins were transferred onto 
nitrocellulose membranes and blocked with bovine serum albumin (BSA; 3% w/v; Sigma-Aldrich) in 
Tris-buffered saline (TBS) containing 0.1% Tween-20 (Sigma-Aldrich) (TBS-T) for 4 h at room 
temperature or overnight at 4 °C. The membranes were incubated with 6E10 (1:2,000, Covance, 
Princeton, NJ, USA) in a solution of BSA (2% w/v in TBS-T) for 2 h at room temperature or overnight 
at 4 °C. After washing with TBS-T (three times, 10 min), a horseradish peroxidase-conjugated goat anti-
mouse secondary antibody (1:5,000 in 2% w/v BSA in TBS-T; Cayman Chemical Company, Ann Arbor, 
MI, USA) was added for 2 h at room temperature. A homemade ECL kit47,77,78 was used to visualize 
gel/Western blot data on a ChemiDoc MP Imaging System (Bio-Rad). 
 
1.4.6. Transmission Electron Microscopy (TEM) 
Samples for TEM were prepared following the previously reported methods.30,32,47,75-77 Glow-discharged 
grids (Formvar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) were treated with 
A samples (5 L, 25 M) for 2 min at room temperature. Excess sample was removed using filter 
paper followed by washing twice with ddH2O. Each grid, incubated with uranyl acetate (5 L, 1% w/v 
ddH2O) for 1 min, was blotted off and dried for 15 min at room temperature. Images for each sample 
were taken on a JEOL JEM-2100 transmission electron microscope (200 kV; 25,000x magnification; 
UCRF). For the TEM studies, we randomly picked the locations of samples on the grids for taking 
images and collected more than 25 images from each grid (sample). 
 
1.4.7. UV–Vis Spectroscopy 
Oxidative transformation of compounds in the absence and presence of A40 with or without metal ions 
[e.g., Cu(II) or Zn(II)] was monitored for 24 h at 37 °C by UV–Vis spectroscopy. Compounds (50 M; 
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1% v/v DMSO) were added into the buffer solution [20 mM HEPES, pH 7.4 [for metal-free or Zn(II)-
containing samples] or pH 6.6 [for Cu(II)-added samples], 150 mM NaCl] with or without A40 (25 M) 
and/or CuCl2 or ZnCl2 (25 M). 
 
1.4.8. Docking Studies 
Flexible ligand docking studies using AutoDock Vina79 for 1–5 were conducted against the A40 
monomer previously determined by NMR [Protein Data Bank (PDB) 2LFM].64 One conformation was 
selected from twenty conformations within the PDB file. The MMFF94 energy minimization in 
ChemBio3D Ultra 11.0 was used to optimize the structure of 1–5 for the docking studies. The structures 
of A40 with 1–5 were prepared in AutoDock Tools80 and imported into PyRx, which was used to run 
AutoDock Vina.73 The exhaustiveness for the docking runs was set at 1,024. Docked models of 1–5 
with the A40 monomer were visualized using Pymol. 
 
1.4.9. Electrospray Ionization–Mass Spectrometry (ESI–MS) 
The ESI–MS experiments were performed following the previously reported methods.47,77 A40 (50 M) 
was incubated with compounds (100 M; 1% v/v DMSO) in 1 mM ammonium acetate (pH 7.4) at 37 °C 
without agitation. The incubated samples were diluted by 10 fold with water and then injected into the 
mass spectrometer. The capillary voltage, sampling cone voltage, and source temperature were set to 
2.8 kV, 40 V, and 40 °C, respectively. The backing pressure was adjusted to 3.37 mbar. Gas flows for 
the helium were set to 180 mL/min. Tandem MS (ESI–MS2) analyses were additionally conducted on 
the singly oxidized metal-free A40 with 1. ESI parameters and experimental conditions were the same 
as above. Collision-induced dissociation (CID) was carried out by applying the collision energy in the 
trap at 45 V and adjusting the low mass (LM) resolution to 4.7 or 10 depending on the samples. More 
than 200 spectra were obtained for each sample and averaged for the analyses. 
 
1.4.10. Matrix-assisted Laser Desorption Ionization–Mass Spectrometry (MALDI–MS) 
A40 (25 M) samples incubated with 1 (50 M; 1% v/v DMSO) and/or metal ions [Cu(II) or Zn(II); 
25 M] in the buffer solution [pH 7.4 for metal-free or Zn(II)-containing samples or pH 6.6 for Cu(II)-
added samples] were incubated at 37 °C for 24 h with constant agitation. Incubated A40, matrix [-
cyano-4-hydroxy-cinnamic acid (5 mg/mL) dissolved in 40% CH3CN and 2% CF3COOH], and 50 M 
of the internal standard were mixed in a ratio of 5:4:1 and loaded on the MALDI–MS target plate. After 
thoroughly drying the samples, MALDI–MS spectra were obtained using an Ultraflex III time-of-flight 
mass spectrometer (UCRF). 
 
1.4.11. Cell Viability Studies 
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N2a cells were maintained in media containing 50% Dulbecco's Modified Eagle Medium (DMEM; 
GIBCO) and 50% Opti-Minimal Essential Medium (Opti-MEM; GIBCO), and supplemented with 5% 
(v/v) fetal bovine serum (FBS; Sigma-Aldrich), 1% (v/v) L-glutamine (GIBCO), 100 U/mL penicillin 
(GIBCO), and 100 mg/mL streptomycin (GIBCO). N2a cells were grown and maintained at 37 °C in a 
humidified atmosphere with 5% CO2. Cell viability upon treatment with compounds was determined 
by the MTT assay. Cells were seeded in a 96-well plate (5,000 cells in 100 L per well) and were treated 
with compounds (5, 10, 25, and 50 M; 1% v/v final DMSO concentration). After 24 h incubation, 
MTT [25 L; 5 mg/mL in PBS (pH 7.4)] was added to each well and the plate was incubated for 4 h at 
37 °C. Formazan produced by cells was solubilized using an acidic solution of N,N-dimethylformamide 
(aq) (DMF; 50% v/v,) and sodium dodecyl sulfate (SDS; 20% w/v) overnight at room temperature in 
the dark. Absorbance was measured at 600 nm by a microplate reader. Cell viability was calculated 
relative to cells containing an equivalent amount of DMSO. The measurements were conducted in 
quadruplicate. 
 
1.4.12. Metabolic Stability 
Compounds (1 M) were added into PBS (0.1 M, pH 7.4; Corning, NY, USA) containing human liver 
microsomes (0.5 mg/mL; Corning) and were incubated for 5 min at 37 °C. The dihydronicotinamide 
adenine dinucleotide phosphate (NADPH; Promega, Madison, WI, USA) regeneration system solution 
was introduced to the pre-incubated mixture and then incubated for 15, 30, and 60 min at 37 °C. To 
terminate the reaction, CH3CN including chlorpropamide known as an internal standard was added. 
After centrifugation (14,000 rpm, 4 °C) for 5 min, the supernatant was injected into the LC-MS/MS 
system (DGMIF) for the analysis. 
 
1.4.13. Brain Uptake Studies 
After 5 min administration of 1 in male CD1 mice [10 mg/kg; per os (p.o.) injection], the mice were 
manually restrained. Blood was taken from the animals via retro-orbital puncture for semi-serial 
bleeding or cardiac puncture (under anesthesia with isoflurane) for terminal bleeding into K2EDTA 
tubes. Blood samples were put on the ice and centrifuged to obtain plasma samples (2,000 g, 5 min 
under 4 °C) within 15 minutes. The animal was euthanized with pure CO2 inhalation. A mid line incision 
was made on the neck. The muscle under the skin was cut to expose the cisterna magna. The cisterna 
magna was penetrated with the sharp end of one capillary. The cerebrospinal fluid (CSF) would be 
sucked spontaneously into the capillary. After CSF collection, a mid-line incision was made in the 
animal’s scalp and skin retracted. The skull overlying the brain was removed. The whole brain was 
collected, rinsed with cold saline, dried on filtrate paper, and weighed; snap frozen by placing into dry 
ice. The supernatant diluted with H2O and CH3OH of each sample (i.e., plasma, brain, and CSF) was 
injected for LC-MS/MS analysis. 
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1.4.14. In Vivo Efficacies 
All animal studies were conducted in accordance with the guidelines of the Asan Institute for Life 
Science for Laboratory Animal Care and Use (Asan Medical Center, Seoul, Republic of Korea). 
Animals were housed with free access to water and food on 12 h light/dark cycle. Our studies used 
5XFAD mice, a transgenic animal model of Alzheimer’s disease (AD) that expresses the 
Swedish/London/Florida mutations of the human amyloid precursor protein (hAPP) and the 
M146L/L286V mutations of the human presenilin-1 (PSEN1) and develops the early and robust AD 
pathology with the cognitive impairments.73 We maintained the mice on a C57BL/6 x SJL hybrid 
background. In vivo efficacy studies were thoroughly performed as previously described.32,33 In brief, 
we daily treated 5XFAD mice by intraperitoneal (i.p.) routes with 1, BQ (1 mg/kg of body weight), or 
the vehicle (1% DMSO in 20 mM HEPES, pH 7.4, 150 mM NaCl) for 30 successive days starting at 
three months of age. From the day of the 30th compound treatments, all animals experienced the Morris 
water maze (MWM) test with three trials per a day for five days to learn the spatial cognitive 
performance. After the last MWM trials, they also performed the probe test at 3 h in the same water 
pool to recall the memory to search for the previous location of the removed target platform. Variable 
parameters of the animal cognitive performance were recorded and evaluated using the SMART video 
tracking system (Harvard Apparatus, Holliston, MA, USA). Immediately after the cognitive 
performance test, the right and left cerebral hemispheres were collected from the brains of sacrificed 
mice for biochemical and histological analysis, respectively. Sandwich enzyme-linked immunosorbent 
assay (ELISA) was conducted to quantify the levels of human A42 (Invitrogen) or oligomeric A (oA; 
Biosensis, Thebarton, South Australia) in PBS-, SDS-, or formic acid (FA)-soluble fractions following 
the serial centrifugal fractionations of the right cerebral hemispheres. To measure the depositions of 
amyloid plaques, the sagittal brain sections, which were prepared from the left hemispheres at 12 m 
thickness, were subjected to A-specific immunohistochemistry and histological staining using the 
human A (17-24)-specific antibody 4G8 (Covance) and Accustain Congo Red amyloid staining 
solution (Sigma-Aldrich), respectively. The immuno-reacted or Congo Red-stained sections were 
examined or photographed under a light microscope (Eclipse 80i; Nikon, Tokyo, Japan). The loads of 
amyloid deposits in the brain were expressed as the percent area of 4G8-immunoreactive deposits or 
the number of congophilic plaques per mm2 of the brain regions of interest (R.O.I.). Values were 
expressed as mean ± standard errors of mean (s.e.m.). Statistical differences between groups were 
evaluated by unpaired t-test or one-way analysis of variance (ANOVA) with Student-Newman-Keuls 
post hoc test, and considered significant at P < 0.05. 
 
1.5. Acknowledgments 
This research is supported by the National Research Foundation of Korea (NRF) grant funded by the 
39 
Korean government [NRF-2016R1A5A1009405 and NRF2017R1A2B3002585 (to M.H.L); NRF-
2015R1A2A1A15052049 (to J.-Y.L.)]; the Korea Advanced Institute of Science and Technology 
(KAIST) (M.H.L.). J.K. acknowledges the Global Ph.D. fellowship program for support through the 
NRF funded by the Ministry of Education (NRF-2015HIA2A1030823). We also thank the previous our 
lab member, Dr. Shin Jung Lee, for initial data and analysis of MALDI–MS. 
 
1.6. References 
1. Apel, K.; Hirt, H. Annu. Rev. Plant Biol. 2004, 55, 373-399. 
2. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T.; Mazur, M.; Telser, J. Int. J. Biochem. Cell 
Biol. 2007, 39, 44-84. 
3. Barnham, K. J.; Masters, C. L.; Bush, A. I. Nat. Rev. Drug Discov. 2004, 3, 205-214. 
4. Uttara, B.; Singh, A. V.; Zamboni, P.; Mahajan, R. T. Curr. Neuropharmacol. 2009, 7, 65-74. 
5. Greenough, M. A.; Camakaris, J.; Bush, A. I. Neurochem. Int. 2013, 62, 540-555. 
6. Kim, G. H.; Kim, J. E.; Rhie, S. J.; Yoon, S. Exp. Neurobiol. 2015, 24, 325-340. 
7. Jenner, P.; Olanow, C. W. Neurology 1996, 47, S161-S170. 
8. Evans, P. H. Br. Med. Bull. 1993, 49, 577-587. 
9. Zhao, Y.; Zhao, B. Oxid. Med. Cell Longev. 2013, 2013, 316523. 
10. Savelieff, M. G.; Nam, G.; Kang, J.; Lee, H. J.; Lee, M.; Lim, M. H. Chem. Rev. 2018, Article 
ASAP. 
11. Maynard, C. J.; Bush, A. I.; Masters, C. L.; Cappai, R.; Li, Q. X. Int. J. Exp. Pathol. 2005, 86, 
147-159. 
12. Martins, R. N.; Villemagne, V.; Sohrabi, H. R.; Chatterjee, P.; Shah, T. M.; Verdile, G.; Fraser, 
P.; Taddei, K.; Gupta, V. B.; Rainey-Smith, S. R.; Hone, E.; Pedrini, S.; Lim, W. L.; Martins, I.; 
Frost, S.; Gupta, S.; O'Bryant, S.; Rembach, A.; Ames, D.; Ellis, K.; Fuller, S. J.; Brown, B.; 
Gardener, S. L.; Fernando, B.; Bharadwaj, P.; Burnham, S.; Laws, S. M.; Barron, A. M.; Goozee, 
K.; Wahjoepramono, E. J.; Asih, P. R.; Doecke, J. D.; Salvado, O.; Bush, A. I.; Rowe, C. C.; 
Gandy, S. E.; Masters, C. L. J. Alzheimers Dis. 2018, 62, 965-992. 
13. Mecocci, P.; Polidori, M. C. Biochim. Biophys. Acta 2012, 1822, 631-638. 
14. Persson, T.; Popescu, B. O. Oxid. Med. Cell Longev. 2014, 2014, 427318. 
15. Kepp, K. P. Chem. Rev. 2012, 112, 5193-5239. 
16. Cheignon, C.; Tomas, M.; Bonnefont-Rousselot, D.; Faller, P.; Hureau, C.; Collin, F. Redox Biol. 
2018, 14, 450-464. 
17. Hardy, J.; Selkoe, D. J. Science 2002, 297, 353-356. 
18. Jakob-Roetne, R.; Jacobsen, H. Angew. Chem. Int. Ed. Engl. 2009, 48, 3030-3059. 
19. DeToma, A. S.; Salamekh, S.; Ramamoorthy, A.; Lim, M. H. Chem. Soc. Rev. 2012, 41, 608-
621. 
40 
20. Savelieff, M. G.; Lee, S.; Liu, Y.; Lim, M. H. ACS Chem. Biol. 2013, 8, 856-865. 
21. Barnham, K. J.; Bush, A. I. Curr. Opin. Chem. Biol. 2008, 12, 222-228. 
22. Barnham, K. J.; Bush, A. I. Chem. Soc. Rev. 2014, 43, 6727-6749. 
23. Li, F.; Calingasan, N. Y.; Yu, F.; Mauck, W. M.; Toidze, M.; Almeida, C. G.; Takahashi, R. H.; 
Carlson, G. A.; Flint Beal, M.; Lin, M. T.; Gouras, G. K. J. Neurochem. 2004, 89, 1308-1312. 
24. Nishida, Y.; Yokota, T.; Takahashi, T.; Uchihara, T.; Jishage, K.; Mizusawa, H. Biochem. 
Biophys. Res. Commun. 2006, 350, 530-536. 
25. Kadowaki, H.; Nishitoh, H.; Urano, F.; Sadamitsu, C.; Matsuzawa, A.; Takeda, K.; Masutani, H.; 
Yodoi, J.; Urano, Y.; Nagano, T.; Ichijo, H. Cell Death Differ. 2005, 12, 19-24. 
26. Rauk, A. Chem. Soc. Rev. 2009, 38, 2698-2715. 
27. Savelieff, M. G.; DeToma, A. S.; Derrick, J. S.; Lim, M. H. Acc. Chem. Res. 2014, 47, 2475-
2482. 
28. Lane, D. J. R.; Ayton, S.; Bush, A. I. J. Alzheimers Dis. 2018, 64, S379-S395. 
29. Schugar, H.; Green, D. E.; Bowen, M. L.; Scott, L. E.; Storr, T.; Bohmerle, K.; Thomas, F.; Allen, 
D. D.; Lockman, P. R.; Merkel, M.; Thompson, K. H.; Orvig, C. Angew. Chem. Int. Ed. Engl. 
2007, 46, 1716-1718. 
30. Lee, S.; Zheng, X.; Krishnamoorthy, J.; Savelieff, M. G.; Park, H. M.; Brender, J. R.; Kim, J. H.; 
Derrick, J. S.; Kochi, A.; Lee, H. J.; Kim, C.; Ramamoorthy, A.; Bowers, M. T.; Lim, M. H. J. 
Am. Chem. Soc. 2014, 136, 299-310. 
31. Derrick, J. S.; Lim, M. H. ChemBioChem 2015, 16, 887-898. 
32. Derrick, J. S.; Kerr, R. A.; Nam, Y.; Oh, S. B.; Lee, H. J.; Earnest, K. G.; Suh, N.; Peck, K. L.; 
Ozbil, M.; Korshavn, K. J.; Ramamoorthy, A.; Prabhakar, R.; Merino, E. J.; Shearer, J.; Lee, J. 
Y.; Ruotolo, B. T.; Lim, M. H. J. Am. Chem. Soc. 2015, 137, 14785-14797. 
33. Beck, M. W.; Derrick, J. S.; Kerr, R. A.; Oh, S. B.; Cho, W. J.; Lee, S. J.; Ji, Y.; Han, J.; Tehrani, 
Z. A.; Suh, N.; Kim, S.; Larsen, S. D.; Kim, K. S.; Lee, J. Y.; Ruotolo, B. T.; Lim, M. H. Nat. 
Commun. 2016, 7, 13115. 
34. Han, J.; Lee, H. J.; Kim, K. Y.; Lee, S. J. C.; Suh, J. M.; Cho, J.; Chae, J.; Lim, M. H. ACS. Chem. 
Neurosci. 2018, 9, 800-808. 
35. Beck, M. W.; Derrick, J. S.; Suh, J. M.; Kim, M.; Korshavn, K. J.; Kerr, R. A.; Cho, W. J.; Larsen, 
S. D.; Ruotolo, B. T.; Ramamoorthy, A.; Lim, M. H. ChemMedChem 2017, 12, 1828-1838. 
36. Cooper, D. L.; Gerratt, J.; Raimondi, M. Nature 1986, 323, 699-701. 
37. Pauling, L. Nature 1987, 325, 396-396. 
38. Messmer, R. P.; Schultz, P. A. Nature 1987, 329, 492-492. 
39. Politzer, P.; Abrahmsen, L.; Sjoberg, P. J. Am. Chem. Soc. 1984, 106, 855-860. 
40. Mecozzi, S.; West, A. P., Jr.; Dougherty, D. A. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 10566-
10571. 
41 
41. Pelzer, K. M.; Cheng, L.; Curtiss, L. A. J. Phys. Chem. C 2017, 121, 237-245. 
42. Walter, R. I. J. Am. Chem. Soc. 1966, 88, 1923-1930. 
43. Janzen, E. G. Acc. Chem. Res. 1969, 2, 279-288. 
44. Re, R.; Pellegrini, N.; Proteggente, A.; Pannala, A.; Yang, M.; Rice-Evans, C. Free Radic. Biol. 
Med. 1999, 26, 1231-1237. 
45. van den Berg, R.; Haenen, G. R. M. M.; van den Berg, H.; Bast, A. Food Chem. 1999, 66, 511-
517. 
46. Arts, M. J. T. J.; Sebastiaan Dallinga, J.; Voss, H.-P.; Haenen, G. R. M. M.; Bast, A. Food Chem. 
2004, 88, 567-570. 
47. Lee, H. J.; Korshavn, K. J.; Nam, Y.; Kang, J.; Paul, T. J.; Kerr, R. A.; Youn, I. S.; Ozbil, M.; 
Kim, K. S.; Ruotolo, B. T.; Prabhakar, R.; Ramamoorthy, A.; Lim, M. H. Chem. Eur. J. 2017, 
23, 2706-2715. 
48. Rao, P. S.; Hayon, E. J. Phys. Chem. 1975, 79, 1063-1066. 
49. Benmehdi, H.; Behilil, A.; Memmou, F.; Amrouche, A. Arab. J. Chem. 2017, 10, S1402-S1408. 
50. Lee, S. J.; Nam, E.; Lee, H. J.; Savelieff, M. G.; Lim, M. H. Chem. Soc. Rev. 2017, 46, 310-323. 
51. Smith, D. P.; Ciccotosto, G. D.; Tew, D. J.; Fodero-Tavoletti, M. T.; Johanssen, T.; Masters, C. 
L.; Barnham, K. J.; Cappai, R. Biochemistry 2007, 46, 2881-2891. 
52. Noy, D.; Solomonov, I.; Sinkevich, O.; Arad, T.; Kjaer, K.; Sagi, I. J. Am. Chem. Soc. 2008, 130, 
1376-1383. 
53. Tougu, V.; Karafin, A.; Zovo, K.; Chung, R. S.; Howells, C.; West, A. K.; Palumaa, P. J. 
Neurochem. 2009, 110, 1784-1795. 
54. Pedersen, J. T.; Ostergaard, J.; Rozlosnik, N.; Gammelgaard, B.; Heegaard, N. H. J. Biol. Chem. 
2011, 286, 26952-26963. 
55. Felice, F. G. D.; Vieira, M. N. N.; Saraiva, L. M.; Figueroa-Villar, J. D.; Garcia-Abreu, J.; Liu, 
R.; Chang, L.; Klein, W. L.; Ferreira, S. T. FASEB J. 2004, 18, 1366-1372. 
56. Meek, A. R.; Simms, G. A.; Weaver, D. F. Can. J. Chem. 2012, 90, 865-873. 
57. Chung, Y.-C.; Su, Y. O. J. Chin. Chem. Soc. 2009, 56, 493-503. 
58. Bai, Y.-H.; Li, J.-Y.; Zhu, Y.-h.; Xu, J.-J. Electroanal. 2010, 22, 1239-1247. 
59. Lauw, S. J. L.; Xu, X.; Webster, R. D. ChemPlusChem 2015, 80, 1288-1297. 
60. Meyer, A.; Fischer, K. Environ. Sci. Eur. 2015, 27, 11. 
61. Lerner, L. J. Phys. Chem. A 2011, 115, 9901-9910. 
62. Sumalekshmy, S.; Gopidas, K. R. Chem. Phys. Lett. 2005, 413, 294-299. 
63. Eyer, P.; Lengfelder, E. Biochem. Pharmacol. 1984, 33, 1005-1013. 
64. Vivekanandan, S.; Brender, J. R.; Lee, S. Y. Biochem. Biophys. Res. Commun. 2011, 411, 312-
316. 
65. Kappus, H.; Sies, H. Experientia 1981, 37, 1233-1241. 
42 
66. Watson, A. A.; Fairlie, D. P.; Craik, D. J. Biochemistry 1998, 37, 12700-12706. 
67. Palmblad, M.; Westlind-Danielsson, A.; Bergquist, J. J. Biol. Chem. 2002, 277, 19506-19510. 
68. Hou, L.; Kang, I.; Marchant, R. E.; Zagorski, M. G. J. Biol. Chem. 2002, 277, 40173-40176. 
69. Hou, L.; Shao, H.; Zhang, Y.; Li, H.; Menon, N. K.; Neuhaus, E. B.; Brewer, J. M.; Byeon, I. J.; 
Ray, D. G.; Vitek, M. P.; Iwashita, T.; Makula, R. A.; Przybyla, A. B.; Zagorski, M. G. J. Am. 
Chem. Soc. 2004, 126, 1992-2005. 
70. Kang, J.; Lee, S. J.; Nam, J. S.; Lee, H. J.; Kang, M. G.; Korshavn, K. J.; Kim, H. T.; Cho, J.; 
Ramamoorthy, A.; Rhee, H. W.; Kwon, T. H.; Lim, M. H. Chem. Eur. J. 2017, 23, 1645-1653. 
71. Vogt, W. Free Radic. Biol. Med. 1995, 18, 93-105. 
72. Stadtman, E. R.; Levine, R. L. Amino Acids 2003, 25, 207-218. 
73. Oakley, H.; Cole, S. L.; Logan, S.; Maus, E.; Shao, P.; Craft, J.; Guillozet-Bongaarts, A.; Ohno, 
M.; Disterhoft, J.; Van Eldik, L.; Berry, R.; Vassar, R. J Neurosci 2006, 26, 10129-10140. 
74. Spencer, V. A.; Sun, J. M.; Li, L.; Davie, J. R. Methods 2003, 31, 67-75. 
75. Choi, J. S.; Braymer, J. J.; Nanga, R. P.; Ramamoorthy, A.; Lim, M. H. Proc. Natl. Acad. Sci. U. 
S. A. 2010, 107, 21990-21995. 
76. Hindo, S. S.; Mancino, A. M.; Braymer, J. J.; Liu, Y.; Vivekanandan, S.; Ramamoorthy, A.; Lim, 
M. H. J. Am. Chem. Soc. 2009, 131, 16663-16665. 
77. Beck, M. W.; Oh, S. B.; Kerr, R. A.; Lee, H. J.; Kim, S. H.; Kim, S.; Jang, M.; Ruotolo, B. T.; 
Lee, J. Y.; Lim, M. H. Chem. Sci. 2015, 6, 1879-1886. 
78. Mruk, D. D.; Cheng, C. Y. Spermatogenesis 2011, 1, 121-122. 
79. Trott, O.; Olson, A. J. J. Comput. Chem. 2010, 31, 455-461. 
80. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. 


































The results, presented in this Chapter, were published or submitted: (1) Yun, J. Y.; Chae, J. B.; Kim, M.; 
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imaging experiments using the newly developed sensors for detection of metal ions in living cells.  
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2.1. Introduction 
Zn2+ plays a key role in biological systems, such as apoptosis and signal transduction.1-5 Dyshomeostasis 
of Zn2+, however, has been suggested as a pathological feature in neurodegenerative diseases [e.g., 
Alzheimer’s disease (AD), Parkinson’s disease, and amyotrophic lateral sclerosis].1-5 In addition to Zn2+, 
the absorption and accumulation of Al3+ in the brain, taken from the environment, diet, and medication, 
has been also reported to be implicated in the pathology of AD.4,6,7 In order to further advance our 
understanding of how abnormal levels and control of metals could affect the pathogenesis of AD, 
visualization of Zn2+ and Al3+ in the brain would help understand their involvement in the disease. Thus, 
as an efficient and effective method, fluorescent imaging to identify the location of metals, utilizing a 
fluorescence-based probe, has been conducted.5,8 In this Chapter, the utilization of the newly 
synthesized three chemosensors for detecting Zn2+ and Al3+ in living cells is described. 
 
2.2. Results and Discussion 
2.2.1. Turn-on Fluorescent Probe, DHIC, for Zn2+ in Living Cells 
To monitor Zn2+ in biological systems, DHIC was synthesized through the condensation reaction of 
imidazole with a water-soluble 4-(diethylamino)salicylaldehyde moiety.9 DHIC (20 M) was pre-
incubated in living cells for 1 h prior to incubation with Zn2+ (600 M) for 1 h. The fluorescent response 
of DHIC to Zn2+ was monitored at the green fluorescence protein (GFP) channel [ex = 470 (± 11) nm; 
em = 510 (± 21) nm; Figure 2.1a]. Furthermore, the DHIC–Zn2+ complex could be applied to detect an 
anion, S2–, among various anions (OAc–, I–, CN–, F–, S2–, SCN–, H2PO4–, Br–, B2O–, N3–, NO2–, and Cl–). 
When S2– (400 M) was incubated with DHIC–Zn2+ for 1 h, the anion was able to interact with Zn2+ 
and consequentially sequester Zn2+ from DHIC. Therefore, we could observe a decrease in fluorescence 
using the GFP channel in the presence of S2– (Figure 2.1b). These results demonstrate the potential 
ability of DHIC as a probe for detecting Zn2+ and S2– in the biological system. 
 






Figure 2.1. Fluorescent imaging of DHIC for Zn2+ with or without S2– in HeLa cells. (a) The cells were 
pre-incubated with DHIC for 1 h prior to treatment with Zn2+. (b) The cells incubated with DHIC for 
1 h were treated with Zn2+ for 1 h. Conditions: [DHIC] = 20 M; [Zn2+] = 600 M; [S2–] = 400 M; 
37 °C; 5% CO2. The scale bar is 50 m. 
 
2.2.2. Turn-on Fluorescent Probe, ATA-DAS, for Zn2+ in Living Cells 
ATA-DAS was newly designed through the combination of thiophene and 4-(diethylamino)salicyl-
aldehyde moieties. To investigate the fluorescent response of ATA-DAS to Zn2+ in living cells, 
fluorescence imaging experiments were conducted in HeLa cells. Our compound, ATA-DAS (30 M), 
was simultaneously incubated with Zn2+ (5 mM) for 10 min with HeLa cells before taking fluorescence 
images. The fluorescence imaging of ATA-DAS in the presence of Zn2+ was observed at the GFP 
channel [ex = 470 (± 11) nm; em = 510 (± 21) nm; Figure 2.2]. In the presence of Zn2+, the fluorescent 
response of ATA-DAS was noticeably increased. Thus, the results of our experiments suggest that ATA-
DAS could be utilized as a chemosensor to detect Zn2+ in biological systems. 
 







Figure 2.2. Fluorescent imaging of ATA-DAS for Zn2+ in HeLa cells. The cells were incubated with 
ATA-DAS and Zn2+ for 10 min. Conditions: [ATA-DAS] = 30 M; [Zn2+] = 5 mM; 37 °C; 5% CO2. 
The scale bar is 50 m. 
 
2.2.3. Turn-on Fluorescent Probe, TPH-Jul, for Al3+ in Living Cells 
TPH-Jul was rationally developed as a probe for Al3+ through the combination of thiophene and 
julolidine moieties. Upon incubation of TPH-Jul (10 M) with various concentrations of Al3+ (i.e., 0.25, 
0.5, 1, and 1.5 m) in living cells, a significant increase in fluorescence was visualized in a 
concentration-dependent manner. The cell imaging was conducted employing the GFP channel [ex = 
470 (± 11) nm; em = 510 (± 21) nm; Figure 2.3]. Together, our results suggest the potential use of TPH-
Jul as a sensor for Al3+ in biological systems.  
 








Figure 2.3. Fluorescent imaging of TPH-Jul for Al3+ in HeLa cells. The cells were incubated with 
TPH-Jul with various concentrations of Al3+ for 2 h. Conditions: [TPH-Jul] = 10 M; [Al3+] = 0.25, 
0.5, 1, and 1.5 mM; 37 °C; 5% CO2. The scale bar is 50 m. 
 
2.3. Conclusion 
Dyshomeostasis of Zn2+ and Al3+ has been suggested to be related to the toxicity found in the AD-
affected brain. In order to obtain a better understanding of the roles of metal ions in the pathology of 
AD, it would be valuable to have effective chemical probes able to selectively detect metal ions. In this 
Chapter, three fluorescent probes, DHIC, ATA-DAS, and TPH-Jul, were newly designed, and 
synthesized, and their ability to visualize metal ions [i.e., Zn2+ (for DHIC and ATA-DAS) and Al3+ (for 
TPH-Jul)] was tested in living cells. In the near future, we will optimize their structures to improve 
their fluorescent responses to metal ions in vitro and in biological systems, as well as their properties 
for bioapplicability. 
 
2.4. Experimental Section  
2.4.1. Imaging Experiments in Living Cells 
HeLa cells (ATCC, Manassas, USA) were maintained in media containing Dulbecco modified eagle 
medium (DMEM), 10% fetal bovine serum (FBS, GIBCO, Grand Island, NY, USA), 100 U/mL 
penicillin (GIBCO), and 100 mg/mL streptomycin (GIBCO). The cells were grown in a humidified 
atmosphere with 5% CO2 at 37 °C. Cells were seeded onto 12 well plate (SPL Life Sciences, Pocheon, 
Gyeonggi-do, Republic of Korea) at a density of 10,000 cells per 100 L and then incubated at 37 °C 
for 16 h. For imaging experiments, the cells were first treated with DHIC (DMSO; 1% v/v final DMSO 
concentration; 20 M) for 1 h, before incubation with Zn(NO3)2 (10 mM bis-tris buffer, pH 7.43, 150 
mM NaCl; 1% v/v final concentration; 600 M) for 1 h. In addition, ii) ATA-DAS (DMSO; 1% v/v 
final DMSO concentration; 30 M) or TPH-Jul (DMSO; 1% v/v final DMSO concentration; 10 M) 
was incubated with Zn(NO3)2 (water; 1% v/v final concentration; 600 M) for 10 min or Al(NO3)3 
(water; 1% v/v final concentration; 0.25, 0.5, 1, and 1.5 mM) for 2 h, respectively. In case of 
fluorescence quenching experiments for DHIC, the cells were treated with DHIC (DMSO; 1% v/v final 
DMSO concentration; 20 M) and Zn(NO3)2 (10 mM bis-tris buffer, pH 7.43, 150 mM NaCl; 1% v/v 
final concentration; 600 M) for 1 h each. Na2S (10 mM bis-tris buffer, pH 7.43, 150 mM NaCl; 1% 
v/v final concentration; 400 M) was treated to the cells for 1 h. Imaging was performed with an EVOS 
FL fluorescence microscope (Life technologies) using a GFP light cube [for DHIC, ATA-DAS, and 
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